Frank Vocci

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Medication development for addictive disorders: the state of the science
    Frank J Vocci
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, 6001 Executive Blvd, Rm 4133, MSC 9551, Bethesda, MD 20892 9551, USA
    Am J Psychiatry 162:1432-40. 2005
  2. ncbi request reprint Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging
    F J Vocci
    Medications Development Division, National Institute on Drug Abuse, Rockville, Maryland 20857, USA
    Ann N Y Acad Sci 820:29-39; discussion 39-40. 1997
  3. ncbi request reprint Vaccines against nicotine: how effective are they likely to be in preventing smoking?
    F J Vocci
    Division of Treatment Research and Development, National Institute on Drug Abuse, Bethesda, Maryland, USA
    CNS Drugs 15:505-14. 2001
  4. ncbi request reprint Medications development: successes and challenges
    Frank Vocci
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Ste 4123, MSC 9551, Bethesda, MD 20892, USA
    Pharmacol Ther 108:94-108. 2005
  5. pmc Modafinil for the treatment of cocaine dependence
    Ann L Anderson
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892 9551, USA
    Drug Alcohol Depend 104:133-9. 2009
  6. pmc Pharmacotherapy of methamphetamine addiction: an update
    Ahmed Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Subst Abus 29:31-49. 2008
  7. ncbi request reprint Bupropion for the treatment of methamphetamine dependence
    Ahmed M Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences, National Institutes of Health, National Institute on Drug Abuse, Bethesda, MD, USA
    Neuropsychopharmacology 33:1162-70. 2008
  8. pmc Novel medications to treat addictive disorders
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Room 4143, Bethesda, MD 20892 9551, USA
    Curr Psychiatry Rep 10:392-8. 2008
  9. ncbi request reprint Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence
    Deborah B Leiderman
    Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Addiction 100:1-11. 2005
  10. ncbi request reprint Biotechnology and the treatment of addictive disorders: new opportunities
    Ahmed Elkashef
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMC, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, Maryland 20892 9551, USA
    BioDrugs 21:259-67. 2007

Detail Information

Publications22

  1. ncbi request reprint Medication development for addictive disorders: the state of the science
    Frank J Vocci
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, 6001 Executive Blvd, Rm 4133, MSC 9551, Bethesda, MD 20892 9551, USA
    Am J Psychiatry 162:1432-40. 2005
    ..Potential medications that modulate these mechanisms are highlighted...
  2. ncbi request reprint Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging
    F J Vocci
    Medications Development Division, National Institute on Drug Abuse, Rockville, Maryland 20857, USA
    Ann N Y Acad Sci 820:29-39; discussion 39-40. 1997
    ..This "harbinger of toxicity" approach would provide clinicians the critical data necessary for appropriate follow-up of subjects as well as the propriety of continuance of the clinical trials within the ibogaine project...
  3. ncbi request reprint Vaccines against nicotine: how effective are they likely to be in preventing smoking?
    F J Vocci
    Division of Treatment Research and Development, National Institute on Drug Abuse, Bethesda, Maryland, USA
    CNS Drugs 15:505-14. 2001
    ..The rationale behind the approach is that nicotine is the pharmacological agent controlling the rate of cigarette smoking, and reducing its rate and extent of uptake into the brain may have therapeutic benefits...
  4. ncbi request reprint Medications development: successes and challenges
    Frank Vocci
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Ste 4123, MSC 9551, Bethesda, MD 20892, USA
    Pharmacol Ther 108:94-108. 2005
    ..Initial studies are underway. Both agonist and antagonist approaches will be evaluated. Additionally, medications will be tested in cannabis-dependent patients for the management of insomnia, withdrawal, and concurrent depression...
  5. pmc Modafinil for the treatment of cocaine dependence
    Ann L Anderson
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892 9551, USA
    Drug Alcohol Depend 104:133-9. 2009
    ..Modafinil was tested for efficacy in facilitating abstinence in cocaine-dependent patients, compared to placebo...
  6. pmc Pharmacotherapy of methamphetamine addiction: an update
    Ahmed Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Subst Abus 29:31-49. 2008
    ..Preclinical data suggest that use of GVG, CB1 antagonist, and lobeline are also promising therapeutic strategies...
  7. ncbi request reprint Bupropion for the treatment of methamphetamine dependence
    Ahmed M Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences, National Institutes of Health, National Institute on Drug Abuse, Bethesda, MD, USA
    Neuropsychopharmacology 33:1162-70. 2008
    ....
  8. pmc Novel medications to treat addictive disorders
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Room 4143, Bethesda, MD 20892 9551, USA
    Curr Psychiatry Rep 10:392-8. 2008
    ..This article reviews the current medications that are medically safe and have shown promising results for treating opioid, cocaine, methamphetamine, and cannabis addictions...
  9. ncbi request reprint Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence
    Deborah B Leiderman
    Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Addiction 100:1-11. 2005
    ....
  10. ncbi request reprint Biotechnology and the treatment of addictive disorders: new opportunities
    Ahmed Elkashef
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMC, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, Maryland 20892 9551, USA
    BioDrugs 21:259-67. 2007
    ..The main focus of this review is on the development of immunotherapy for stimulants and nicotine addiction as a model highlighting the current status of the science and potential emerging discoveries and development...
  11. doi request reprint Clinical management of drug addicts infected with human immunodeficiency virus and hepatitis C virus
    Jag H Khalsa
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, NIH, 6001 Executive Boulevard, Bethesda, MD 20892, USA
    J Addict Dis 27:1-10. 2008
    ..Clinical management of substance abusers with infections is possible, available, and effective if individuals in drug treatment programs are closely monitored for adherence and compliance to HIV/HCV treatment regimens...
  12. ncbi request reprint Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence
    Ahmed Elkashef
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Addiction 100:91-101. 2005
    ..Pooling data from these small pilot trials into four major drug classes permitted data exploration for treatment and covariate effects with increased sample size...
  13. ncbi request reprint Prevalence of abnormal liver-associated enzymes in cocaine experienced adults versus healthy volunteers during phase 1 clinical trials
    Louis R Cantilena
    Division of Clinical Pharmacology and Medical Toxicology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799, USA
    Contemp Clin Trials 28:695-704. 2007
    ..The potential to obscure important signals for hepatotoxicity during Phase 1 research may be higher in the CE study population...
  14. ncbi request reprint Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence
    Ahmed Elkashef
    National Institute on Drug Abuse NIDA, Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMCDA, MSC 9551 Bethesda, MD 20892, USA
    Drug Alcohol Depend 85:191-7. 2006
    ..The contrast of this result to earlier, promising preclinical and human pilot data could be due to factors associated with sample size, patient characteristics, dose, or poor predictive validity of preclinical models...
  15. ncbi request reprint Biological markers of cocaine addiction: implications for medications development
    Ahmed Elkashef
    Division of Treatment, Research and Development DTR and D, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Addict Biol 8:123-39. 2003
    ..Merging the biology within medications studies of cocaine abusers could prove useful for targeting specific pharmacological agents to subgroups of patients, prediction of response to medication and relapse to use...
  16. ncbi request reprint The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity
    Ahmed Elkashef
    Division of Treatment Research and Development, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Addiction 102:107-13. 2007
    ..This multi-site infrastructure would serve to run multiple Phases II and III protocols effectively and expeditiously...
  17. pmc Marijuana neurobiology and treatment
    Ahmed Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Subst Abus 29:17-29. 2008
    ..The next few years looking promising for translational research efforts to make treatment widely accessible to patients with marijuana dependence...
  18. ncbi request reprint Intravenous cocaine and QT variability
    Mark C P Haigney
    Division of Cardiology, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    J Cardiovasc Electrophysiol 17:610-6. 2006
    ..Dynamic instability in cardiac repolarization may contribute to drug-induced arrhythmogenesis. We hypothesized that intravenous cocaine would significantly destabilize repolarization as measured by QT variability...
  19. ncbi request reprint The challenging interactions between antiretroviral agents and addiction drugs
    Jag Khalsa
    Center on AIDS and Other Medical Consequences of Drug Abuse CAMCODA, National Institute on Drug Abuse, NIH, Rockville, MD, USA
    Am Clin Lab 21:10-3. 2002
  20. ncbi request reprint The SRPHK1 outcome measure for cocaine-dependence trials combines self-report, urine benzoylecgonine levels, and the concordance between the two to determine a cocaine-use status for each study day
    Eugene Somoza
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Drug Alcohol Depend 93:132-40. 2008
    ....
  21. ncbi request reprint 6-[18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter
    Yu Shin Ding
    Chemistry Department, Brookhaven National Laboratory, Upton, New York 11973, USA
    Synapse 53:184-9. 2004
  22. ncbi request reprint Cocaine Rapid Efficacy Screening Trials (CREST): lessons learned
    Kyle M Kampman
    Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
    Addiction 100:102-10. 2005
    ....